Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.110
-0.020 (-1.77%)
At close: Feb 13, 2026, 4:00 PM EST
1.120
+0.010 (0.90%)
After-hours: Feb 13, 2026, 7:43 PM EST

Pliant Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
--1.589.697.5741.82
Revenue Growth (YoY)
---83.69%27.91%-81.89%-26.70%
Gross Profit
--1.589.697.5741.82
Selling, General & Admin
54.7559.0657.9339.9527.5617.27
Research & Development
135.17169.31127.896.9477.5566.19
Operating Expenses
189.92228.37185.73136.89105.1183.46
Operating Income
-189.92-228.37-184.15-127.2-97.54-41.65
Interest Expense
-3.26-3.02-1.27-0.79--
Interest & Investment Income
13.8721.0924.084.670.270.11
Pretax Income
-175.5-210.3-161.34-123.32-97.26-41.53
Net Income
-175.5-210.3-161.34-123.32-97.26-41.53
Net Income to Common
-175.5-210.3-161.34-123.32-97.26-41.53
Shares Outstanding (Basic)
616159423621
Shares Outstanding (Diluted)
616159423621
Shares Change (YoY)
1.52%3.10%39.75%17.21%67.94%1214.82%
EPS (Basic)
-2.87-3.47-2.75-2.94-2.71-1.95
EPS (Diluted)
-2.87-3.47-2.75-2.94-2.71-1.95
Free Cash Flow
-158.79-159.35-117.28-96.39-77.4-38.8
Free Cash Flow Per Share
-2.59-2.63-2.00-2.29-2.16-1.82
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---11654.75%-1313.37%-1288.10%-99.59%
Profit Margin
---10211.14%-1273.32%-1284.51%-99.32%
Free Cash Flow Margin
---7422.91%-995.26%-1022.13%-92.79%
EBITDA
-188.13-226.24-182.3-125.38-96-40.34
EBITDA Margin
------96.46%
D&A For EBITDA
1.792.131.841.821.541.31
EBIT
-189.92-228.37-184.15-127.2-97.54-41.65
EBIT Margin
------99.59%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q